OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SHKE59

S H Kelkar and Company Ltd

Specialty ChemicalsVerified

S H Kelkar and Company Ltd maintains a debt-to-equity ratio of 0.65, indicating a moderate reliance on debt financing, and a current ratio of 1.39, suggesting adequate short-term liquidity to cover its obligations. However, the company's free cash flow of 626.6 million INR is significantly lower than its capital expenditure of 957.3 million INR, indicating a net cash outflow from operations that may require external financing to fund ongoing investments. The company's profitability metrics show a return on equity (ROE) of 5.76% and a return on assets (ROA) of 2.73%, both of which are below the typical thresholds for high-performing specialty chemical firms. These figures suggest that the company is not generating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of 1.47 billion INR on revenue of 21.23 billion INR, is 6.93%, which is in line with the industry median for specialty chemicals but leaves room for improvement in cost control and pricing power. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segment or geographic diversification increases the company's exposure to sector-specific and regional economic risks. The absence of detailed segment reporting also limits the ability to assess the performance of individual product lines or markets. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the current or next fiscal year. The capital expenditure of 957.3 million INR suggests ongoing investment in infrastructure and production capacity, but the free cash flow of 626.6 million INR indicates that these investments are not being fully funded by internal cash generation. The company may need to rely on external financing or asset sales to sustain its investment program. The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is currently low, as the number of shares outstanding has not changed between basic and diluted shares, and there are no indications of recent or planned equity issuances that would dilute existing shareholders. However, the company's reliance on debt financing and the need for additional capital to fund capital expenditures could increase dilution risk in the future. Recent filings and transcripts do not provide specific details on the company's strategic initiatives or operational performance. However, the consistent price target of 270.00 INR from analysts suggests a stable outlook, with a strong buy recommendation from one analyst and no conflicting opinions. This consensus may reflect confidence in the company's long-term position in the specialty chemicals market, despite its current financial constraints.

30-day price · SHKE-9.27 (-6.8%)
Low$119.11High$158.87Close$127.50As of22 May, 00:00 UTC
Profile
CompanyS H Kelkar and Company Ltd
TickerSHKE.NS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. S H Kelkar and Company Ltd is a specialty chemicals manufacturer that produces and distributes a range of chemical products for industrial and commercial applications, generating revenue primarily through the sale of these products.

Classification. The company is classified under the Basic Materials economic sector, within the Chemicals business sector and the Specialty Chemicals industry, with a classification confidence of 0.92.

S H Kelkar and Company Ltd maintains a debt-to-equity ratio of 0.65, indicating a moderate reliance on debt financing, and a current ratio of 1.39, suggesting adequate short-term liquidity to cover its obligations. However, the company's free cash flow of 626.6 million INR is significantly lower than its capital expenditure of 957.3 million INR, indicating a net cash outflow from operations that may require external financing to fund ongoing investments. The company's profitability metrics show a return on equity (ROE) of 5.76% and a return on assets (ROA) of 2.73%, both of which are below the typical thresholds for high-performing specialty chemical firms. These figures suggest that the company is not generating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of 1.47 billion INR on revenue of 21.23 billion INR, is 6.93%, which is in line with the industry median for specialty chemicals but leaves room for improvement in cost control and pricing power. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segment or geographic diversification increases the company's exposure to sector-specific and regional economic risks. The absence of detailed segment reporting also limits the ability to assess the performance of individual product lines or markets. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the current or next fiscal year. The capital expenditure of 957.3 million INR suggests ongoing investment in infrastructure and production capacity, but the free cash flow of 626.6 million INR indicates that these investments are not being fully funded by internal cash generation. The company may need to rely on external financing or asset sales to sustain its investment program. The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is currently low, as the number of shares outstanding has not changed between basic and diluted shares, and there are no indications of recent or planned equity issuances that would dilute existing shareholders. However, the company's reliance on debt financing and the need for additional capital to fund capital expenditures could increase dilution risk in the future. Recent filings and transcripts do not provide specific details on the company's strategic initiatives or operational performance. However, the consistent price target of 270.00 INR from analysts suggests a stable outlook, with a strong buy recommendation from one analyst and no conflicting opinions. This consensus may reflect confidence in the company's long-term position in the specialty chemicals market, despite its current financial constraints.
Key takeaways
  • S H Kelkar and Company Ltd has a moderate debt-to-equity ratio and adequate short-term liquidity, but its free cash flow is insufficient to cover capital expenditures.
  • The company's ROE and ROA are below industry benchmarks, indicating suboptimal returns on equity and assets.
  • Revenue is concentrated in a single business segment, with no geographic diversification disclosed, increasing exposure to sector-specific and regional risks.
  • Analysts have assigned a strong buy rating with a consistent price target of 270.00 INR, suggesting confidence in the company's long-term prospects despite current financial constraints.
  • The company's liquidity risk is moderate, and dilution risk is currently low, but ongoing capital expenditures may require external financing in the future.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$21.23B
Gross profit$8.86B
Operating income$1.47B
Net income$732.4M
R&D
SG&A
D&A
SBC
Operating cash flow$203.0M
CapEx-$957.3M
Free cash flow$626.6M
Total assets$26.85B
Total liabilities$14.13B
Total equity$12.72B
Cash & equivalents
Long-term debt$8.32B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$12.72B
Net cash-$8.32B
Current ratio1.4
Debt/Equity0.7
ROA2.7%
ROE5.8%
Cash conversion28.0%
CapEx/Revenue-4.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricSHKEActivity
Op margin6.9%5.5% medp25 -0.0% · p75 10.8%above median
Net margin3.4%4.1% medp25 0.1% · p75 8.8%below median
Gross margin41.7%20.5% medp25 12.4% · p75 29.7%top quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-4.5%-6.2% medp25 -13.4% · p75 -2.6%above median
Debt / equity65.0%37.1% medp25 10.3% · p75 82.0%above median
Observations
IR observations
Mean price target270.00 INR
Median price target270.00 INR
High price target270.00 INR
Low price target270.00 INR
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate4.40 INR
Last actual EPS5.26 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 16:33 UTC#7081037b
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 10:13 UTCJob: d5726c72